Triple-Negative Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019
Nancy Lin, MD, discusses advances in research and treatment for patients with triple-negative metastatic breast cancer. Triple-negative breast cancer, which accounts for about 15% of all breast cancers, are a prime example of how quickly immunotherapy has become a standard part of treatment. Where patients were once treated with chemotherapy regimens, those whose tumors test positive for the PD-L1 checkpoint protein may now receive a checkpoint inhibitor along with chemotherapy at some point during their treatment.
Dr. Lin provides an overview of current research in triple-negative breast cancer, including trials for PARP inhibitors, immunotherapy, and antibody-drug conjugates. She shared results of a recent trial for patients whose tumors had worsened after standard chemotherapy. Treatment with the conjugate drug sacituzumab caused many of these participants’ tumors to shrink.
For more information about clinical trials for metastatic breast cancer, please visit https://www.dana-farber.org/metastatic-breast-cancer-program/clinical-research-and-trials/
This information was presented at the EMBRACE Metastatic Breast Cancer Forum at Dana-Farber in October 2019.
EMBRACE (Ending Metastatic Breast Cancer for Everyone) is a Dana-Farber Cancer Institute program designed to offer metastatic breast cancer patients the best care possible by combining our expertise in clinical care and clinical research. As part of the program, our patients are offered a variety of supportive care resources and presented with emerging clinical trial opportunities in a personalized and ongoing basis. If you live a distance away, our care team can also collaborate with you and your local oncologist during your treatment. Near or far, we are here to provide active, continuous care to help you achieve the highest possible quality of life and make informed decisions about your care.
For more information about the EMBRACE Program, please visit https://www.dana-farber.org/metastatic-breast-cancer-program/
Видео Triple-Negative Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019 канала Dana-Farber Cancer Institute
Dr. Lin provides an overview of current research in triple-negative breast cancer, including trials for PARP inhibitors, immunotherapy, and antibody-drug conjugates. She shared results of a recent trial for patients whose tumors had worsened after standard chemotherapy. Treatment with the conjugate drug sacituzumab caused many of these participants’ tumors to shrink.
For more information about clinical trials for metastatic breast cancer, please visit https://www.dana-farber.org/metastatic-breast-cancer-program/clinical-research-and-trials/
This information was presented at the EMBRACE Metastatic Breast Cancer Forum at Dana-Farber in October 2019.
EMBRACE (Ending Metastatic Breast Cancer for Everyone) is a Dana-Farber Cancer Institute program designed to offer metastatic breast cancer patients the best care possible by combining our expertise in clinical care and clinical research. As part of the program, our patients are offered a variety of supportive care resources and presented with emerging clinical trial opportunities in a personalized and ongoing basis. If you live a distance away, our care team can also collaborate with you and your local oncologist during your treatment. Near or far, we are here to provide active, continuous care to help you achieve the highest possible quality of life and make informed decisions about your care.
For more information about the EMBRACE Program, please visit https://www.dana-farber.org/metastatic-breast-cancer-program/
Видео Triple-Negative Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019 канала Dana-Farber Cancer Institute
Показать
Комментарии отсутствуют
Информация о видео
28 ноября 2019 г. 1:09:00
00:22:26
Другие видео канала
Triple Negative Breast Cancer: What you need to knowHER2 Positive Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019How a triple-negative breast cancer survivor became cancer-freeChemotherapy Options for Triple Negative Breast CancerStrategies to Reduce the Risk of Cancer RecurrenceER-Positive Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019Understanding Breast Cancer Biology: New Discoveries and Treatments2021 San Antonio Breast Cancer Symposium Update on MBC | 2021-2022 EMBRACE MBC Virtual Forum SeriesAt 32, She Faced Rare Triple-Negative Breast Cancer: ‘My Story can Help a Lot of People’Triple Negative Breast Cancer Case Panel Discussion | 2022 Best of Breast ConferenceTriple-negative breast cancers, everything you've always wanted to know | ECP SymposiumBench To Bedside S8E13: The Future of Triple-Negative Breast Cancer TreatmentTriple Negative Breast Cancer: What You Need to KnowMedical update: Triple-negative breast cancer with Rita Nanda, MDAsk the expert: Triple-negative breast cancer with Elaine Walsh, MB BCh BAO, PhDDiscovery of the year - Triple negative breast cancerSurgical Management of Breast Cancer - Jennifer Baker, MD | UCLAMDChatImmunotherapy and Triple Negative Breast Cancer - Mayo Clinic11/19/2020: Triple Negative Breast Cancer: The Elusive Search for TargetsWhat is triple-negative breast cancer? | Dana-Farber Cancer Institute